SCHEMBL4256579

SCHEMBL4256579

NC(=O)c1ccc(F)cc1Br.O=S(=O)(O)/C=C/c1csc2ccccc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.38
PTGS2 P35354 1/20 0.38
CA12 O43570 2/20 0.37
CA9 Q16790 2/20 0.37
CA2 P00918 2/20 0.37
CA1 P00915 1/20 0.37
MAPT P10636 4/20 0.36
MAOB P27338 1/20 0.36
CYP2A6 P11509 1/20 0.36
TUBB4A P04350 1/20 0.35
TUBB P07437 1/20 0.35
TUBA3C P0DPH7 1/20 0.35
TUBA1B P68363 1/20 0.35
TUBA4A P68366 1/20 0.35
TUBB4B P68371 1/20 0.35
TUBB3 Q13509 1/20 0.35
TUBB2A Q13885 1/20 0.35
TUBB8 Q3ZCM7 1/20 0.35
TUBA3E Q6PEY2 1/20 0.35
TUBA1A Q71U36 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4256645 0.89 PTGS1 (0.39) PTGS1PTGS2CA12CA9CA2
SCHEMBL4267080 0.86 PTGS1 (0.37) PTGS1PTGS2CA12CA9CA2
SCHEMBL4260199 0.82 MAPT (0.39) PTGS1PTGS2CA12CA9CA2
SCHEMBL4260203 0.82 MAPT (0.39) PTGS1PTGS2CA12CA9CA2
SCHEMBL4260387 0.80 PTGS1 (0.40) PTGS1PTGS2CA12CA9CA2
SCHEMBL27717791 0.80 NFE2L2 (0.40) CA12CA9CA2CA1MAPT
SCHEMBL5404000 0.80 NFE2L2 (0.40) CA12CA9CA2CA1MAPT
SCHEMBL5426631 0.79 ALDH1A1 (0.44) MAOBMEN1ALDH1A1KMT2AHTR2A
SCHEMBL27717784 0.79 ALDH1A1 (0.44) MAOBMEN1ALDH1A1KMT2AHTR2A
SCHEMBL4255148 0.78 CES2 (0.39) PTGS1PTGS2CA12CA9CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904471-B1 HETEROARYLETHENYL DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS HOFFMANN LA ROCHE (CH) 2009-10-21 EP claimed
US-7208506-B2 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US claimed
EP-1904471-B1 HETEROARYLETHENYL DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS HOFFMANN LA ROCHE (CH) 2009-10-21 EP disclosed
US-7208506-B2 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US disclosed
US-20070010564-A1 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010564-A1 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents CYP3A43, CYP1A1, CYP3A5 PTGS1 285/4885PTGS2 550/4885CA12 4435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.